Nektar's IL-2 Impresses In Combination With Bristol's Opdivo

 
• By Emily Hayes

Nektar's IL-2 stimulating agonist NKTR-214 combines well with Bristol's Opdivo in Phase I PIVOT-02 study presented at SITC meeting in November.

T-cells attacking cancer_1200x675

More from Immuno-oncology

More from Anticancer